Table 1.

Changes in Percentages of Memory B Cells as a Result of Vaccination or Wild-Type Challenge

	Effect of Placebo		Effect of Vaccination				Effect of Challenge
	90 Days After Administration of Placebo* (n = 33)		90 Days Post-Vaccination * (n = 33)		180 Days Post-Vaccination* (n = 22)		170 Days Post-Challenge* (n = 26)
Measurement	Median Ratio➉: Day 90/Day 0 (95% CI)	p-value	Median Ratio➉: Day 90/Day 0 (95% CI)	p-value	Median Ratio➉,§: Day 180/Day 0 (95% CI)	p-value	Median Ratio➉,§: Day 180/Day 0 (95% CI)	p-value
% LPS-specific IgA BM	0.9 [0.7, 1.2]	0.57	1.3 [0.9, 2.5]	0.16	2.1 [1.2, 6.6]	0.001	3.1 [2.0, 8.8]	< 0.001
% LPS-specific IgG BM	0.7 [0.5, 1.1]	0.07	1.2 [0.8, 2.7]	0.15	3.9 [0.9, 9.1]	0.004	6.2 [2.6, 13.5]	< 0.001
% CT-specific IgA BM	1.1 [0.8, 1.6]	0.32	1.2 [0.9, 1.4]	0.23	1.1 [0.7, 1.4]	0.74	1.7 [1.2, 2.6]	< 0.001
% CT-specific IgG BM	1.0 [0.8, 1.2]	0.79	1.5 [1.2, 1.9]	< 0.001	2.4 [1.8, 3.7]	< 0.001	13.2 [5.1, 24.9]	< 0.001

^*Note that each of the four groups in Table 1 is composed of a unique set of subjects.

^➉A ratio of 1.0 indicates no change from the Day 0 percentage of memory B cells.

^§The duration of post-challenge follow-up through Day 180 was slightly shorter than the post-vaccination duration through Day 180 since challenge occurred on Day 10 and vaccination occurred on Day 0 (170 days vs. 180 days).